top of page
Browse by category
Search
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with...
Lilly's Zepbound (tirzepatide) achieved total mean weight loss of 26.0% from baseline to 88 weeks
Detailed results from SURMOUNT-4 have shown Zepbound (tirzepatide) injection achieved superior mean percent change in body weight...
Zepbound (tirzepatide) available in US pharmacies for adults living with obesity
Eli Lilly and Company has announced that Zepbound (tirzepatide) injection is now available in US pharmacies for adults with obesity (with...
FDA approves Lilly's Zepbound (tirzepatide) for chronic weight management
The FDA has approved Eli Lilly and Company's Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that...
Browse by tag
bottom of page